109 related articles for article (PubMed ID: 25593234)
1. Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.
van Weely SF; Dekker J; Steultjens MP; van Denderen JC; Nurmohamed MT; Dijkmans BA; van der Horst-Bruinsma IE
J Rheumatol; 2015 Apr; 42(4):623-9. PubMed ID: 25593234
[TBL] [Abstract][Full Text] [Related]
2. What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.
van Weely SF; van Denderen JC; Steultjens MP; Nurmohamed MT; Dijkmans BA; Dekker J; van der Horst-Bruinsma IE
Rheumatology (Oxford); 2013 Oct; 52(10):1884-9. PubMed ID: 23864170
[TBL] [Abstract][Full Text] [Related]
3. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
Nossent JC; Sagen-Johnsen S; Bakland G
J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy.
So MW; Heo HM; Koo BS; Kim YG; Lee CK; Yoo B
J Rheumatol; 2012 Sep; 39(9):1854-8. PubMed ID: 22859343
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of performance measures of physical function based on the BASFI, in ankylosing spondylitis.
van Weely SF; van Denderen CJ; van der Horst-Bruinsma IE; Nurmohamed MT; Dijkmans BA; Dekker J; Steultjens MP
Rheumatology (Oxford); 2009 Oct; 48(10):1254-60. PubMed ID: 19638455
[TBL] [Abstract][Full Text] [Related]
7. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial.
Masiero S; Bonaldo L; Pigatto M; Lo Nigro A; Ramonda R; Punzi L
J Rheumatol; 2011 Jul; 38(7):1335-42. PubMed ID: 21459942
[TBL] [Abstract][Full Text] [Related]
8. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
9. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
10. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.
Gulyas K; Bodnar N; Nagy Z; Szamosi S; Horvath A; Vancsa A; Vegh E; Szabo Z; Szucs G; Szekanecz Z; Szanto S
Eur J Health Econ; 2014 May; 15 Suppl 1():S93-100. PubMed ID: 24832840
[TBL] [Abstract][Full Text] [Related]
11. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
[TBL] [Abstract][Full Text] [Related]
13. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
Prince DS; McGuigan LE; McGirr EE
Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
16. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
[TBL] [Abstract][Full Text] [Related]
18. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
20. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
